Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000062787

Apexbio Technology LLC Oprozomib (ONX-0912) 935888-69-0 10mM (in 1mL DMSO)
SDP

Catalog No. 5000062787
Encompass_Preferred

Oprozomib (ONX-0912 CAS 935888-69-0) is an orally bioavailable small-molecule inhibitor of the proteasome structurally related to carfilzomib It targets predominantly the chymotrypsin-like proteolytic activity of the proteasome inducing apoptosis and growth inhibition in multiple myeloma (MM) cell lines including those resistant to bortezomib In preclinical models oprozomib activates pro-apoptotic pathways involving caspases-3 -8 -9 as well as PARP cleavage suppresses angiogenesis and tumor cell migration thereby reducing tumor progression and prolonging survival Its biological activity positions oprozomib as a promising compound for MM research

Catalog No. 50-000-62787 Supplier Apexbio Technology LLC Supplier No. A19345.1
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Oprozomib (ONX-0912 CAS 935888-69-0) is an orally bioavailable small-molecule inhibitor of the proteasome structurally related to carfilzomib It targets predominantly the chymotrypsin-like proteolytic activity of the proteasome inducing apoptosis and growth inhibition in multiple myeloma (MM) cell lines including those resistant to bortezomib In preclinical models oprozomib activates pro-apoptotic pathways involving caspases-3 -8 -9 as well as PARP cleavage suppresses angiogenesis and tumor cell migration thereby reducing tumor progression and prolonging survival Its biological activity positions oprozomib as a promising compound for MM research

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.